Loading
Life sciences · Journal article
Discover Oncology · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
OSCC (Oral Squamous Cell Carcinoma) is a prevalent head and neck malignancy, accounting for about 90% of oral cancers. According to the GCO (Global Cancer Observatory), the incidence of OSCC will increase by approximately 40% by 2040. OSCC may cause disfigurement and functional impairments, including difficulties with swallowing, speech, and taste, significantly impacting patients’ quality of life and even causing death. Clarifying the molecular mechanisms and developing more effective treatments for OSCC are important. This review focuses on the molecular mechanisms of key signaling pathways in OSCC, such as EGFR pathway, PI3K/AKT pathway, Wnt pathway, JAK/STAT pathway, MET pathway, MAPK pathway, PD-1/PD-L1 pathway, Hippo pathway, EMT pathway, and so on. It emphasizes their composition, the molecules involved in their regulation, inhibitory signals that inactivate OSCC, clinical studies, and targeted therapies associated with these signal pathways. We highlight targeted therapies such as cetuximab, gefitinib, and nivolumab for their therapeutic potential in treating OSCC. Overall, understanding these interconnected signaling networks can accelerate the development of more effective and personalized therapies for OSCC.